Medicare now reimburses Lucid Diagnostics’ EsoGuard esophageal DNA test at $1,938 per test, following its $15 million private ...
Hologic has agreed to acquire Reveal Genomics, adding the HER2DX assay to its breast cancer genomic testing portfolio, the ...
Abbott’s WGS-based Oncodetect MRD test showed a 30% sensitivity improvement for post-surgical colorectal cancer recurrence.
FDA grants bioMérieux dual clearance and CLIA waiver for the BIOFIRE SPOTFIRE Vaginitis Panel, a rapid 20-minute ...
Biodesix, in partnership with Bio-Rad and Thermo Fisher Scientific, advances tumor-informed and tumor-naïve MRD assays for ...
Hologic and Inpeco have partnered to connect Panther Systems with FlexLab X automation in Europe, aiming to improve ...
A study finds permissive lab screening thresholds double primary aldosteronism detection rates versus Endocrine Society ...
Quest Diagnostics and Waters will expand at-home HPV screening in 2027, offering extended genotyping via the Onclarity ...
Illumina has introduced three early-access software capabilities on its BioInsight Platform designed to automate informatics ...
A study reports that liquid biopsy tests can detect early lung cancer recurrence months before imaging in NSCLC patients.
Revvity Signals Software launches Signals LabGistics, an AI-based platform designed to coordinate lab workflows and support GxP compliance across R&D and manufacturing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results